NT-proBNP as a means of triage for the risk of hospitalisation in primary care

European Journal of Preventive Cardiology

Volumn 19, Issue 1, 2012, Pages 55-61

  Adlbrecht, Christopher ^a   Neuhold, Stephanie ^a   Hülsmann, Martin ^a   Strunk, Guido ^b   Ehmsen, Udo ^c   Scholten, Christine ^c   Maurer, Gerald ^a   Pacher, Richard ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b Research Institute for Complex Systems   (Austria)

^c NONE   (Austria)

Author keywords

Hospitalisation; NT proBNP; primary care; risk

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

AGED; ARTICLE; CARDIOVASCULAR MORTALITY; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; EMERGENCY HEALTH SERVICE; FEMALE; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE FUNCTION; HOSPITALIZATION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OBSERVATIONAL STUDY; PREDICTIVE VALUE; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECEIVER OPERATING CHARACTERISTIC; RISK; SYSTOLIC DYSFUNCTION; ADULT; CARDIOVASCULAR RISK; CLINICAL FEATURE; CONTROLLED STUDY; DIAGNOSTIC VALUE; FOLLOW UP; HEART LEFT VENTRICLE EJECTION FRACTION; OUTCOME ASSESSMENT; PROTEIN BLOOD LEVEL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SENSITIVITY AND SPECIFICITY;

AGED; AGED, 80 AND OVER; AUSTRIA; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CHI-SQUARE DISTRIBUTION; FEMALE; HOSPITALIZATION; HUMANS; LINEAR MODELS; MALE; MASS SCREENING; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PRIMARY HEALTH CARE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; TIME FACTORS; TRIAGE;

EID: 84856941359     PISSN: 20474873     EISSN: 20474881     Source Type: Journal    
DOI: 10.1177/1741826710391545     Document Type: Article

References (17)

1. McMurray JJ, Stewart S. Epidemiology, aetiology, and prognosis of heart failure. Heart 2000; 83: 596–602.
2. Hobbs FD, Korewicki J, Cleland JG, Eastaugh J, Freemantle N. The diagnosis of heart failure in European primary care: The IMPROVEMENT Programme survey of perception and practice. Eur J Heart Fail 2005; 7: 768–779.
3. Wannamethee SG, Welsh P, Whincup PH., et al High adiponectin and increased risk of cardiovascular disease and mortality in asymptomatic older men: does NT-proBNP help to explain this association?. Eur J Cardiovasc Prev Rehabil 2010 May 25. [Epub ahead of print].
4. Mostaza JM, Lahoz C, Martin-Jadraque R., et al Factors associated with the discontinuation of evidence-based cardiovascular therapies in patients with stable coronary artery disease: a primary care perspective. Eur J Cardiovasc Prev Rehabil 2009; 16: 34–38.
5. Fonseca C. Diagnosis of heart failure in primary care. Heart Fail Rev 2006; 11: 95–107.
6. Jones RH, Velazquez EJ, Michler RE., et al Coronary bypass surgery with or without surgical ventricular reconstruction. N Engl J Med 2009; 360: 1705–1717.
7. McMurray J, Ostergren J, Pfeffer M., et al Clinical features and contemporary management of patients with low and preserved ejection fraction heart failure: baseline characteristics of patients in the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity (CHARM) programme. Eur J Heart Fail 2003; 5: 261–270.
8. Resl M, Neuhold S, Riedl M., et al NT-proBNP and cardiac events in older diabetic patients. Eur J Cardiovasc Prev Rehabil in press.
9. Dunlay S, Redfield M, Weston S., et al Hospitalizations after heart failure diagnosis a community perspective. J Am Coll Cardiol 2009; 54: 1695–1702.
10. Kannel WB, Hjortland M, Castelli WP. Role of diabetes in congestive heart failure: the Framingham study. Am J Cardiol 1974; 34: 29–34.
11. Lloyd-Jones DM, Larson MG, Leip EP., et al Lifetime risk for developing congestive heart failure: the Framingham Heart Study. Circulation 2002; 106: 3068–3072.
12. Ellis LB, Allison RB, Rodriguez FL, Robbins SL. Relation of the degree of coronary-artery disease and of myocardial infarctions to cardiac hypertrophy and chronic congestive heart failure. N Engl J Med 1962; 266: 525–529.
13. The SOLVD Investigators Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. N Engl J Med 1992; 327: 685–691.
14. Ahmed A, Allman RM, Fonarow GC., et al Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Cardiac Fail 2008; 14: 211–218.
15. Hulsmann M, Berger R, Mortl D., et al Incidence of normal values of natriuretic peptides in patients with chronic heart failure and impact on survival: a direct comparison of N-terminal atrial natriuretic peptide, N-terminal brain natriuretic peptide and brain natriuretic peptide. Eur J Heart Fail 2005; 7: 552–556.
16. Stanek B, Frey B, Hulsmann M., et al Prognostic evaluation of neurohumoral plasma levels before and during beta-blocker therapy in advanced left ventricular dysfunction. J Am Coll Cardiol 2001; 38: 436–442.
17. Nielsen OW, Cowburn PJ, Sajadieh A., et al Value of BNP to estimate cardiac risk in patients on cardioactive treatment in primary care. Eur J Heart Fail 2007; 9: 1178–1185.